Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion
about
Oncolytic virotherapy for pediatric malignancies: future prospectsCharacteristics of lung cancers harboring NRAS mutationsA chromatin-mediated reversible drug-tolerant state in cancer cell subpopulationsA comprehensive survey of Ras mutations in cancer.Ras, an actor on many stages: posttranslational modifications, localization, and site-specified events.Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.Lung adenocarcinoma subtypes based on expression of human airway basal cell genesNF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.Spatial cycles in G-protein crowd controlTargeting pediatric cancer stem cells with oncolytic virotherapyTemporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse alleleIn vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1.Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.Comparative study of mutations in SNP loci of K-RAS, hMLH1 and hMSH2 genes in neoplastic intestinal polyps and colorectal cancer.KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations.A genome-wide RNAi screen in mouse embryonic stem cells identifies Mp1 as a key mediator of differentiation.ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold.SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling.Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice.Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiationActivated k-ras, but not h-ras or N-ras, regulates brain neural stem cell proliferation in a raf/rb-dependent manner.Cancer stem cell drugs target K-ras signaling in a stemness context.Ras acylation, compartmentalization and signaling nanoclusters (Review).Isoform-specific ras functions in development and cancer.Mutant KRAS is a druggable target for pancreatic cancer.Degradation of activated K-Ras orthologue via K-Ras-specific lysine residues is required for cytokinesis.Non-redundancy within the RAS oncogene family: insights into mutational disparities in cancer.Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity.Lineage factors and differentiation states in lung cancer progression.Opposite feedback from mTORC1 to H-ras and K-ras4B downstream of SREBP1.IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal.Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.RAS Proteins and Their Regulators in Human Disease.AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/Monitoring Ras Interactions with the Nucleotide Exchange Factor Son of Sevenless (Sos) Using Site-specific NMR Reporter Signals and Intrinsic Fluorescence.KRAS mutation associated with CD44/CD166 immunoexpression as predictors of worse outcome in metastatic colon cancer.Rapalogs can promote cancer cell stemness in vitro in a Galectin-1 and H-ras-dependent manner.Functional specificity of ras isoforms: so similar but so different.Rare codons regulate KRas oncogenesis.New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels.
P2860
Q28069358-A90FA794-5C34-4F0A-92F8-FDB1769D9B23Q28706226-5444B0B4-FEC3-475D-9348-318E29A1B887Q29614275-13328CC2-F981-41F8-8ADA-126BE2E51BF5Q30416821-75E7DDA7-8DAE-4A89-97C3-DE8FB7771464Q33351823-8C1AB05B-502B-4C9E-85B7-49320CCEB03BQ33825288-012E57A7-3450-4BBC-B2AA-E00F7E06AF88Q34013536-B83C108F-8463-48AC-A10B-53450CC8D22BQ34031980-EAE501E0-38F5-42F6-82AD-BAE0AC8A3A0BQ34076266-A357A40F-89AE-4B48-B6E5-974F5AD51FD7Q34262327-97A7DC58-3A62-4380-8E82-F33982FA8E12Q34273969-3DCC9464-0017-4292-B60F-34038021995BQ34488339-B0DE6BAD-CE26-4C23-9F84-02161B975DB6Q34667782-E117FC19-E62B-4811-AB57-3113C5F36A54Q34779174-8BA62DFF-3409-4D1C-9CD5-F17F776E05D3Q35083740-1D039016-891A-4B66-A564-E1CBC6CD329FQ35627696-FEE69E09-E6F3-4175-993A-A017A66FF84EQ36082699-2EE05073-B5AE-4858-8F9C-D90862488449Q36098356-D8B12680-57A6-427D-9092-BF8A48DA4391Q36634430-C54ADE2C-10C1-4247-8B7D-63EBB2500908Q36771749-319B62AE-4BA6-42F3-9000-7ACD611D892EQ36956839-2DC07C30-3220-40EC-8C5C-0F0F583EC14DQ37325194-D7A8F4B7-F196-4D9D-8A1C-27BF7782E25EQ37359986-B178A23C-5B57-46EE-B451-452436E6BF43Q37401355-57AC44CD-6B95-4E26-B83B-17301F9B9873Q37409321-5DA90B4B-C20D-40CE-AF1C-15F4EF17D647Q37583441-15302D86-531E-49B3-8C5D-53F45DD47335Q37610817-CBE8C180-75D4-4E0C-A8CC-D89984725AB1Q37662428-583719D5-C4D5-431D-9E9F-5A7D30669E06Q38395972-CB342296-1C2A-412D-8350-69C25D63A5E3Q38615220-A8585341-292C-4980-8E89-277567464D15Q38733973-59A8803F-0DA3-453E-9569-E1D8396B903DQ38953667-8836795C-26CA-4DF1-8526-83EFB49CF2D3Q39407402-6AB97C91-9C0D-4B6A-B815-2D9A8D455A26Q39459058-EF335B86-7E77-4F16-8BD8-6B04F5289862Q40325189-3A12CCE0-7FDB-4DB2-8CAE-7343F3E78336Q40808702-29FDC1FB-3039-41C0-B7F6-EBEE72A61A9DQ41280171-985FB5BC-B854-4FA6-84BD-274719F5446AQ42784309-A9BFA774-AADA-4AAA-B44C-28D077A5E375Q43220010-7B641D3D-CFB9-4B44-BA75-93E9492AF423Q47621738-B193648B-6D55-4939-8031-4B61A72F6B51
P2860
Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Activated Kras, but not Hras o ...... origin via stem cell expansion
@en
type
label
Activated Kras, but not Hras o ...... origin via stem cell expansion
@en
prefLabel
Activated Kras, but not Hras o ...... origin via stem cell expansion
@en
P2093
P2860
P356
P1476
Activated Kras, but not Hras o ...... origin via stem cell expansion
@en
P2093
Jeffrey Settleman
Margaret P Quinlan
Mark R Philips
Steven E Quatela
P2860
P304
P356
10.1128/MCB.01661-07
P407
P577
2008-02-11T00:00:00Z